First Week of NTRA March 20th Options Trading

Natera (NTRA) trades at $234.97 and the article outlines two income strategies: selling a $230 put (bid $12.80) would set an effective purchase basis of $217.20 and carries a 59% probability of expiring worthless, implying a 5.57% cash-return (32.26% annualized) YieldBoost. Alternatively, selling a $240 covered call (bid $13.70) against shares yields 7.97% if called at the March 20 expiration, a 5.83% (33.80% annualized) YieldBoost with a 50% chance of expiring worthless; implied volatility is ~44–45% versus a 12-month realized volatility of 40%.

Analysis

MARKET STRUCTURE: The options market is pricing modestly elevated risk for NTRA (IV 44–45% vs realized 40%), implying limited tail fear but meaningful near-term event risk through the March 20 expiry. Sellers of short-dated premium (puts at $230 bid $12.80; calls $240 bid $13.70) directly benefit — they collect a 5.6–5.8% cash boost (~32–34% annualized) vs buyers who pay for optionality and face assignment risk. This is a short-dated volatility capture trade rather than a fundamental re-rating of Natera’s market share or pricing power in diagnostics/biotech.

RISK ASSESSMENT: Tail risks are binary clinical/regulatory outcomes and biotech-wide risk-off that could swing IV +20–40 pts and move shares ±30–60% in days; liquidity could evaporate on a headline. Immediate (days) risk: assignment or large IV move into earnings; short-term (weeks to March 20): premium decay and 50–59% odds of expiring worthless; long-term (quarters): fundamentals (revenue cadence, reimbursement, test adoption) dominate. Hidden dependency: selling puts implicitly leverages balance-sheet exposure to a company with event-driven jump-to-default/regulatory risk.

TRADE IMPLICATIONS: Direct plays — if target is to accumulate NTRA, sell cash-secured $230 puts size 1–2% portfolio to achieve $217.20 basis (collect $12.80), but cap exposure and limit to notional equal to intended position. Alternative: buy 100 NTRA at $234.97 and sell the $240 call (Mar20) to pocket $13.70 (max upside ~7.97% to expiry); treat as tactical income for 3–6 week window. For volatility: consider calendar buy (buy 90–120d calls, sell Mar20 calls) if you expect IV contraction post-event; avoid naked short vol absent hedges.

CONTRARIAN ANGLES: Consensus treats this as an income trade; what's missing is binary event risk — the ~59%/50% odds imply market is roughly coin-flip on direction but undervalues potential IV repricing if a readout hits. Reaction may be underdone: IV premium is only ~5 pts over realized, so selling premium is not “rich” — but assignment risk makes cash-secured puts effectively a leveraged long with asymmetric downside. Historical parallels: biotech short-dated premium often rapidly reprice around headlines; a single negative press release can erase the YieldBoost and spike IV 2x, so size and hedges matter.

Key Decisions for Investors

• If you want exposure to NTRA, establish a cash-secured put position: sell-to-open 1–2% portfolio equivalent in $230 Mar20 puts (collect $12.80) to target a $217.20 basis; limit aggregate biotech option exposure to <5% capital and cap position loss with a stop if stock < $200 (≈15% from current).
• For income with limited directional conviction, buy 100 NTRA at ~$235 and sell the $240 Mar20 covered call (receive $13.70) for a tactical ~8% return to expiry; close or roll if IV rises >10 pts or share >$250 before Mar20 to avoid adverse assignment.
• If you view IV as mean-reverting and want to harvest term structure: implement a calendar (buy 90–120d calls, sell Mar20 calls) size 0.5–1% portfolio to collect theta while retaining upside; exit if implied vol differential narrows to <5 pts or after any major clinical/earnings headline.
• Avoid naked short puts/calls larger than 2% portfolio before confirming absence of binary catalysts; monitor for catalysts over next 30–60 days (earnings, clinical readouts, reimbursement news) and reduce option-selling if IV jumps >15 pts or OI concentrates >30% of average daily volume.